Proteomics and precision treatment for severe limb-threatening PAD (CLTI)
Official title: Proteomics, outcomes and precision treatment of patients with chronic limb threatening ischemia (CLTI).
Funded at New York University School of Medicine · NIH-11465702 · Data updated 2026-11-12
A patient-facing look at using blood protein data to predict outcomes and guide safer, more effective treatment for people with the most severe peripheral artery disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 10, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $872,787 |
| NIH project number | 1R01HL183504-01A1 |
| Project ID | NIH-11465702 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with chronic limb threatening ischemia or related peripheral artery disease who are or could be considered for rivaroxaban or similar antithrombotic therapies.
✕Less likely to help
Patients not yet diagnosed with CLTI or without access to targeted antithrombotic strategies may not directly benefit.
What this research studies
This project aims to use detailed blood protein measurements to predict who with chronic limb threatening ischemia will have major limb or heart events and who might benefit most from a specific antithrombotic therapy. By combining data from large patient groups and a major rivaroxaban trial, researchers hope to identify protein signatures that signal risk and treatment response. The work includes adding lipid measurements to enrich understanding of vascular disease and using real-world clinical outcomes to improve precision care. If successful, clinicians could tailor therapies to reduce bad events while minimizing bleeding risk for CLTI patients.
Why it matters
Potential benefit: If successful, patients with CLTI could receive more personalized therapies that reduce major complications while minimizing treatment harms.
How similar studies have gone: Prior studies show that protein signatures can relate to cardiovascular risk, but this exact CLTI-focused proteomics approach with rivaroxaban therapy is novel and exploratory.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Newman, Jonathan D — New York University School of Medicine
- Study coordinator: Newman, Jonathan D
Related research
Other NIH-funded projects on the same topics.
-
Tailored treatment paths for people with severe limb-threatening leg artery disease
This grant aims to use advanced analytics to create personalized treatment sequences for adults with chronic limb-threatening ischemia to improve survival and limb preservation.
-
Improving Chronic Limb-Threatening Ischemia in the U.S.
A nationwide study aims to understand why some people with severe leg artery disease progress to limb-threatening conditions and amputation, with an emphasis on Black adults and other communities.
-
Fatty scarring in severe leg ischemia
Researchers are seeing whether changing a cell signal called Hedgehog can reduce fat and scar tissue in calf muscles and help people with severe poor blood flow to the leg regain better blood flow and muscle function.
-
Using stem cells to improve blood flow in patients with severe leg ischemia
This study is testing a new way to help veterans with chronic limb threatening ischemia, a serious condition that can lead to losing a limb, by using special cells to improve blood flow and heal damaged blood vessels.
-
Investigating how fatty fibrosis affects severe limb ischemia
This study is looking at how fatty fibrosis affects people with chronic limb threatening ischemia (CLTI), a condition that causes poor blood flow and can lead to severe pain or even amputation, to find new ways to improve blood flow and muscle function in those struggling with this issue.
-
Using machine learning to predict disease progression and survival in patients with severe limb ischemia.
This study is working on a smart system that helps doctors understand how serious chronic limb-threatening ischemia (CLTI) is for patients and how it changes over time, so they can give the best treatment possible and improve health outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.